Virios Therapeutics (VIRI) Tops Q3 EPS by 20c; Reports Cash Position of $19.2M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 11, 2021 7:05 AM ESTOver 200 patients Enrolled in Fibromyalgia Phase 2b Trial Filed Investigational New Drug Application with FDA to Assess IMC-1 Potential to Treat Irritable Bowel Syndrome Cash Position Supports Operations into Q1 2023 Management to Host Webcast and Conference Call at 8:30 a.m. EST November 11, 2021
ATLANTA--(BUSINESS WIRE)-- Virios Therapeutics, Inc. (Nasdaq:... More
